These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31810594)

  • 41. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.
    Srivastava A; Kahan M; Njoroge I; Sommer LZ
    Can Fam Physician; 2019 May; 65(5):e214-e220. PubMed ID: 31088887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study.
    Dupouy J; Palmaro A; Fatséas M; Auriacombe M; Micallef J; Oustric S; Lapeyre-Mestre M
    Ann Fam Med; 2017 Jul; 15(4):355-358. PubMed ID: 28694272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
    Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge.
    Proctor SL; Birch A; Herschman PL
    J Addict Med; 2019; 13(2):113-118. PubMed ID: 30199427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.
    Lofwall MR; Havens JR
    Drug Alcohol Depend; 2012 Dec; 126(3):379-83. PubMed ID: 22704124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only.
    El Ibrahimi S; Hallvik S; Johnston K; Leichtling G; Korthuis PT; Chan B; Hartung DM
    J Subst Abuse Treat; 2022 Jan; 132():108615. PubMed ID: 34600772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
    Mittal L; Suzuki J
    Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
    Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH
    Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).
    D'Onofrio G; Edelman EJ; Hawk KF; Pantalon MV; Chawarski MC; Owens PH; Martel SH; VanVeldhuisen P; Oden N; Murphy SM; Huntley K; O'Connor PG; Fiellin DA
    Implement Sci; 2019 May; 14(1):48. PubMed ID: 31064390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.